InMed Pharmaceuticals, Inc. (IMLFF) is a Player in the Billion Dollar Cannabis Biotech Market
Despite the fire-breathing from Attorney-General Jefferson Beauregard Sessions III, there is a distinct feeling that marijuana has entered the mainstream now that Goldman Sachs has initiated coverage on GW Pharma (NASDAQ: GWPH). GW Pharma is the biopharmaceutical that developed the cannabinoid-derived Sativex to treat spasticity due to multiple sclerosis (MS), now approved by regulatory authorities in 29 countries. The success of GW Pharma and other pharmaceutical companies focused on cannabinoid research has produced an exciting new field with a lot of promise, cannabis biotech, and InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is staking a position in that emerging market.…